Cantor Fitzgerald Reiterates “$27.00” Price Target for Spero Therapeutics (SPRO)

Cantor Fitzgerald set a $27.00 price objective on Spero Therapeutics (NASDAQ:SPRO) in a report published on Thursday. The brokerage currently has a buy rating on the stock.

Several other research analysts have also issued reports on SPRO. Oppenheimer set a $30.00 target price on Spero Therapeutics and gave the stock a buy rating in a research report on Monday, December 18th. Zacks Investment Research raised Spero Therapeutics from a hold rating to a buy rating and set a $14.00 target price for the company in a research report on Tuesday, January 30th. Finally, ValuEngine raised Spero Therapeutics from a strong sell rating to a sell rating in a research report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $24.25.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:SPRO opened at $15.49 on Thursday. Spero Therapeutics has a 52-week low of $9.66 and a 52-week high of $19.00. The company has a market capitalization of $256.49 and a PE ratio of -0.87.

Spero Therapeutics (NASDAQ:SPRO) last announced its earnings results on Monday, April 2nd. The company reported ($1.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.77) by $0.18. The firm had revenue of $0.99 million during the quarter, compared to the consensus estimate of $0.40 million. research analysts expect that Spero Therapeutics will post -4.94 earnings per share for the current fiscal year.

Several large investors have recently made changes to their positions in the company. TIAA CREF Investment Management LLC bought a new position in shares of Spero Therapeutics in the 4th quarter worth approximately $103,000. California State Teachers Retirement System bought a new position in Spero Therapeutics during the 4th quarter valued at approximately $112,000. Dean Capital Investments Management LLC bought a new position in Spero Therapeutics during the 4th quarter valued at approximately $118,000. Deutsche Bank AG bought a new position in Spero Therapeutics during the 4th quarter valued at approximately $155,000. Finally, California Public Employees Retirement System bought a new position in Spero Therapeutics during the 4th quarter valued at approximately $294,000. 46.28% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Cantor Fitzgerald Reiterates “$27.00” Price Target for Spero Therapeutics (SPRO)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/15/cantor-fitzgerald-reiterates-27-00-price-target-for-spero-therapeutics-spro.html.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections.

Analyst Recommendations for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply